Pharmaceuticals, Biotechnology and Life Sciences
Zealand Pharma has reported royalty revenue from Sanofi’s sales of Lyxumia (lixisenatide) outside the United States of €0.7 million for Q4 2016 and annual royalty revenue of €3.3 million in 2016.
U.S. Food and Drug Administration (FDA) has granted a French based biopharmaceutical company Cellectis an Investigational New Drug (IND) approval to start first phase clinical trial with UCART123 in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Kiadis Pharma has started its phase III trial with its major products for blood cancer hematopoietic stem cell transplantation (HSCT) ATIR101.
Portola Pharmaceuticals has signed a $150 million royalty deal with HealthCare Royalty Partners (HCR).
U.S. Food and Drug Administration (FDA) has approved Bristol-Myers’s Opdivo injection, for treatment of urothelial carcinoma (mUC).
Japan IP High Court confirmed validity of Eli Lilly’s Alimta vitamin regimen patents, and has invalidated trials initiated by Sawai regarding Lilly’s vitamin regimen patents for Alimta.
Pfizer has reported 11% growth for full-year 2016 revenues, reaching $52.8 billion, including the business from Hospira and the legacy of Medivation. Net income for full year was $7,215 million which is up 4% from last years total net income of $6,960.
BioMarin Pharmaceutical’s treatment for hemophilia has been accepted for PRIME (Priority Medicines) scheme from the European Medicines Agency (EMA).
Sanofi announced on Wednesday two approvals for its drugs in North America. Rheumatoid arthritis drug, which it has made in cooperation with Regeneron Pharmaceuticals, has been approved by Health Canada and the U.S. Food and Drug Administration (FDA) has approved Xyzal Allergy 24HR
Several leaders of some of the largest pharmaceutical companies have met on Tuesday with the newly elected US president, Donald Trump to discuss industry related topics, agreeing that the talks were positive.